![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Vladimir Krasnik, Jana Stefanickova, Ivajlo Popov, Jela Valaskova, Sandeep Saxena & Peter Kruzliak. (2018) Prevalence of Age-Related Macular Degeneration in Slovakia and Associated Risk Factors: A Mobile Clinic-Based Cross-Sectional Epidemiological Survey. Seminars in Ophthalmology 33:4, pages 506-511.
Read now
Read now
Panagiotis G. Mitropoulos, Irini P. Chatziralli, Vasileios G. Peponis, Evangelos Drakos & Efstratios A. Parikakis. (2015) Intravitreal Ranibizumab for the Treatment of Irvine-Gass Syndrome. Ocular Immunology and Inflammation 23:3, pages 225-231.
Read now
Read now
Articles from other publishers (26)
Lu Teng, Yabin Sun, Siying Teng & Peng Hui. (2023)
Applications of nanomaterials in
anti‐VEGF
treatment for ophthalmic diseases
. Journal of Biomedical Materials Research Part A 112:2, pages 296-306.
Crossref
Crossref
Haibei Ma, Hai Wei, Chunpu Zou, Guoqin Zhu, Qi Gao, Ning Zhang & Bing Wang. (2023) Anti-VEGF Drugs in Age-Related Macular Degeneration: A Focus on Dosing Regimen-Related Safety and Efficacy. Drugs & Aging 40:11, pages 991-1007.
Crossref
Crossref
Prerna Sharma, Rahul V. Joshi, Robert Pritchard, Kevin Xu & Maya A. Eicher. (2023) Therapeutic Antibodies in Medicine. Molecules 28:18, pages 6438.
Crossref
Crossref
Yanbin Zeng, Xiaohui Guo, Fengjiao Xiao & Haixia Zhang. (2023) Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: An Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database. The Journal of Clinical Pharmacology 63:8, pages 909-917.
Crossref
Crossref
Dhyana Sharma, Ian Zachary & Haiyan Jia. (2023) Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases. Investigative Opthalmology & Visual Science 64:5, pages 28.
Crossref
Crossref
Zhibin Wang, Zhaobo Zhang, Yue Wang & Yu Di. (2022) Effect of ranibizumab on retinopathy of prematurity: A meta-analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Neeraj Nainwal, Tejas Chirmade, Kayanat Gani, Sunil Rana & Rahul Bhambure. (2022) Understanding unfolding and refolding of the antibody fragments (Fab). II. Mapping intra and inter-chain disulfide bonds using mass spectrometry. Biochemical Engineering Journal 182, pages 108439.
Crossref
Crossref
Veeral Sheth, Mitchell D'Rozario, Shamika Gune & Steven Blotner. (2022) Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis. BMJ Open Ophthalmology 7:1, pages e000957.
Crossref
Crossref
Igor Kozak, Avinash Gurbaxani, Ammar Safar, Prasan Rao, Amal Masalmeh, Hazar Assaf, Mohamed Farghaly, Prathamesh Pathak, Ashok Natarajan & Insaf Saffar. (2021) Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai. PLOS ONE 16:7, pages e0254569.
Crossref
Crossref
Adnan Tufail, Philippe Margaron, Tadhg Guerin & Michael Larsen. (2020) Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA. British Journal of Ophthalmology 104:5, pages 672-677.
Crossref
Crossref
Timothy Y. Y. LaiGiovanni StaurenghiPaolo LanzettaFrank G. HolzShiao Hui Melissa LiewSabine Desset-BrethesHarry Staines & Philip G. Hykin. (2018) EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE. Retina 38:8, pages 1464-1477.
Crossref
Crossref
Giovanni Staurenghi, Timothy Y.Y. Lai, Paul Mitchell, Sebastian Wolf, Andreas Wenzel, Jun Li, Amitabha Bhaumik & Philip G. Hykin. (2018) Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes. Ophthalmology 125:6, pages 850-862.
Crossref
Crossref
Yu-Ping Jia, Lei Sun, He-Shui Yu, Li-Peng Liang, Wei Li, Hui Ding, Xin-Bo Song & Li-Juan Zhang. (2017) The Pharmacological Effects of Lutein and Zeaxanthin on Visual Disorders and Cognition Diseases. Molecules 22:4, pages 610.
Crossref
Crossref
Emily D. Cole, Daniela Ferrara, Eduardo A. Novais, Ricardo N. Louzada & Nadia K. Waheed. (2016) CLINICAL TRIAL ENDPOINTS FOR OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina 36:Supplement 1, pages S83-S92.
Crossref
Crossref
Saima Subhani, Divya Teja Vavilala & Mridul Mukherji. (2016) HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies. Angiogenesis 19:3, pages 257-273.
Crossref
Crossref
Eduardo A. Novais, Emmerson Badaró, Flavio E. Hirai, Felipe Abdo Jorge, Paula Leal, Michel Eid Farah & Eduardo B. Rodrigues. (2016) Daily Optical Coherence Tomography Examinations after First Antivascular Endothelial Growth Factor Injections: An Interventional Case Series. Journal of Ophthalmology 2016, pages 1-6.
Crossref
Crossref
Elizabeth R. Lorden, Howard M. Levinson & Kam W. Leong. (2013) Integration of drug, protein, and gene delivery systems with regenerative medicine. Drug Delivery and Translational Research 5:2, pages 168-186.
Crossref
Crossref
Maciej Szemraj, Anna Bielecka-Kowalska, Katarzyna Oszajca, Marta Krajewska, Roman Goś, Piotr Jurowski, Michał Kowalski & Janusz Szemraj. (2015) Serum MicroRNAs as Potential Biomarkers of AMD. Medical Science Monitor 21, pages 2734-2742.
Crossref
Crossref
Panagiotis G. Mitropoulos, Irini P. Chatziralli, Efstratios A. Parikakis, Vasileios G. Peponis, Georgios A. Amariotakis & Marilita M. Moschos. (2014) Intravitreal Ranibizumab for Stage IV Proliferative Sickle Cell Retinopathy: A First Case Report. Case Reports in Ophthalmological Medicine 2014, pages 1-6.
Crossref
Crossref
M El Sanharawi, E Touchard, R Benard, P Bigey, V Escriou, C Mehanna, M-C Naud, M Berdugo, J-C Jeanny & F Behar-Cohen. (2013) Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularization. Gene Therapy 20:11, pages 1093-1103.
Crossref
Crossref
A. Wolf, L. Reznicek, J. Muhr, M. Ulbig, A. Kampik & C. Haritoglou. (2012) Rezidivbehandlung der neovaskulären altersbedingten Makuladegeneration mit Ranibizumab nach dem PrONTO-SchemaTreatment of recurrent neovascular age-related macular degeneration with ranibizumab according to the PrONTO scheme. Der Ophthalmologe 110:8, pages 740-745.
Crossref
Crossref
Murat Aslankurt, Lokman Aslan, Adnan Aksoy, Burak Erden & Osman Çekiç. (2013) The Results of Switching between 2 Anti-VEGF Drugs, Bevacizumab and Ranibizumab, in the Treatment of Neovascular Age-related Macular Degeneration. European Journal of Ophthalmology 23:4, pages 553-557.
Crossref
Crossref
James E. Frampton. (2013) Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration. Drugs & Aging 30:5, pages 331-358.
Crossref
Crossref
David Xu & Peter K Kaiser. (2013) Intravitreal aflibercept for neovascular age-related macular degeneration. Immunotherapy 5:2, pages 121-130.
Crossref
Crossref
Xinrong Xu, Li Hang, Binglin Huang, Yuanhua Wei, Shizhong Zheng & Wei Li. (2013)
Efficacy of Ethanol Extract of
Fructus lycii
and Its Constituents Lutein/Zeaxanthin in Protecting Retinal Pigment Epithelium Cells against Oxidative Stress:
In Vivo
and
In Vitro
Models of Age-Related Macular Degeneration
. Journal of Ophthalmology 2013, pages 1-10.
Crossref
Crossref
Christina L. Grant, Leslie A. Caromile, Khayyam Durrani, M. Mamunur Rahman, Kevin P. Claffey, Guo-Hua Fong & Linda H. Shapiro. (2012) Prostate Specific Membrane Antigen (PSMA) Regulates Angiogenesis Independently of VEGF during Ocular Neovascularization. PLoS ONE 7:7, pages e41285.
Crossref
Crossref